ABSTRACT
In recent years, U.S. Food and Drug Administration (FDA)-approved GLP-1 medicines have surged in popularity as treatments for diabetes and obesity. A temporary shortage of these drugs opened the door to a flood of unapproved knock-offs from compounding pharmacies looking to cash in. The shortage has ended, but some compounders continue to mass produce compounded knock-offs, which ignores longstanding limits on compounding and puts patients at risk.
Unlike FDA-approved drugs manufactured under strict standards, compounded drugs are not subject to FDA approval and are never reviewed by the Agency for safety, efficacy, or quality. Regulators and public health experts have repeatedly warned that compounded drugs carry unique, heightened safety risks and should not be used when FDA-approved drugs are available. Compounding was intended as a narrow exception—for patients whose needs can’t be met by approved drugs—not for mass-producing untested products.
The rise of large-scale compounding of GLP-1 drugs raises grave concerns. And those concerns are magnified by compounders’ disregard for the law. Even after the FDA made clear that mass compounding of semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) must stop, some compounders continue to manufacture and sell these unapproved products. Lax enforcement of longstanding legal limits on compounding has allowed this dangerous practice to persist— endangering patients and threatening another preventable public health crisis.
This report outlines the critical role of FDA’s drug approval system in protecting patients and underscores how enforcement failures undermine drug safety and regulatory integrity.
READ FULL REPORT HERE
READ PRESS RELEASE HERE
